0RC7 Stock Chart & Stats
kr29.04
-kr19.80(-18.94%)
At close: 4:00 PM EDT
kr29.04
-kr19.80(-18.94%)
Day’s Range― - ―
52-Week Rangekr23.57 - kr42.96
Previous CloseN/A
Volume2.39K
Average Volume (3M)28.96K
Market Cap
kr3.49B
Enterprise Valuekr4.01K
Total Cash (Recent Filing)kr552.81M
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Nov 05, 2026EPS Estimate
5.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume43,390
30 Day Avg. Volume28,964
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr103.00Price Target Upside254.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr442.61M
Bulls Say, Bears Say
Bulls Say
Robust Phase III/confirmatory EfficacyLarge, statistically significant improvements in eGFR and marked reductions in dialysis dependence provide durable clinical differentiation versus standard care. This strengthens the case for regulatory approvals, durable clinician adoption and formulary inclusion, undergirding long-term commercial potential in transplant care.
Transformative Out-licensing CashThe EUR 110m upfront materially extends runway and funds commercial build‑out and regulatory work ahead of U.S. approval. This non‑operational cash infusion reduces near‑term refinancing risk, enabling execution on launch readiness and strategic optionality without immediate dilution.
Product Momentum And Unit EconomicsQoQ sales acceleration and multi‑country traction (Spain reimbursement, strength in France/Italy/Germany/UK) indicate early commercial uptake. Combined with consistently high gross margins (~60% TTM), this points to durable product‑level profitability as volumes scale with further market access and potential U.S. launch.
Bears Say
Negative Equity And Elevated LeverageA negative equity base with roughly 1.03B in debt materially constrains financial flexibility for a small biotech. Persistent losses could exacerbate solvency risk, increase refinancing costs, and limit the firm's ability to invest opportunistically or absorb setbacks during the commercial scale‑up phase.
Sustained Cash BurnDeep, persistent negative operating and free cash flow indicate reliance on external funding unless operating losses narrow. Even with the SERB upfront, ongoing cash burn to support launch, SG&A and regulatory costs creates a long‑term dependency on partnerships or capital markets to sustain commercialization.
Sharp Revenue Decline And Large LossesA ~54% TTM revenue drop and very large negative net margins reflect failure to achieve scale relative to cost base. Rising SG&A for U.S. launch has widened operating losses, meaning profitable scale remains distant and execution risk on commercialization and reimbursement must be overcome for durable financial improvement.
0RC7 FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest share price was kr23.57 and its highest was kr42.96 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr3.49B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 96 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -kr2.56 earnings per share for the quarter, missing the consensus estimate of -kr0.337 by -kr2.223.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 5.76.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr2.56 in its last earnings report, missing expectations of -kr0.337. Following the earnings report the stock price went up 0.395%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in GB:0RC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
0RC7 Stock 12 Month Forecast
Average Price Target
kr103.00
▲(254.68% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―